New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /...
Coverage criteria consistent with recent FDA clearance for NeuroStar TMSMALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
NEW YORK, July 19, 2024 /PRNewswire/ -- With a 20 year career in producing data-driven solutions for clients at Amazon...
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic...
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up...
Taught by renowned Zen Master and author Henry Shukman, new app offers program of long-term meditation training that guides users...
Full analysis of first-in-class CNS-101 study measuring functional neurophysiology at home in patients living with mild Alzheimer's dementiaPoster presentations scheduled for the...
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava...
Company strengthens sustainability practices prior to commercializationEINDHOVEN, the Netherlands, July 17, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD),...
MIAMI BEACH, Fla., July 16, 2024 /PRNewswire/ -- ShiraTronics, a trailblazing clinical-stage neurostimulation company, proudly presented findings from its Australian...
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15,...
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024...
Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for...
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data...
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-CalMALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE)...
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001...
Pragmatic registry provides high-quality real-world data on Alzheimer's disease, dementia, and mild cognitive impairment for research PALO ALTO, Calif. , July 10,...
The Fresh Start Award Program will grant up to five individuals a one-time prize of $10,000 to help them reach...